Can tirzepatide help with hidradenitis suppurativa?

Why does weight matter so much in hidradenitis suppurativa?

HS is driven by inflammation in the hair follicles of skin-fold areas, the armpits, groin, buttocks and under the breasts are the most common sites. It is not caused by poor hygiene, and most people with it have tried many treatments before they find anything that helps consistently. Obesity does not cause HS, but it worsens it through several routes. Excess adipose tissue produces pro-inflammatory cytokines that amplify the immune dysregulation already central to HS. Skin folds create friction and a warm, moist environment that accelerates flares. Mechanical pressure on affected tissue makes healing harder. Studies have consistently shown that people with HS who lose meaningful amounts of weight often see a reduction in lesion count and severity scores. The question now being asked is whether the means of achieving that weight loss (specifically GLP-1 receptor agonists) adds anything on top of the weight reduction itself.

The NHS patient information page for tirzepatide explains how the medicine works on appetite and blood-sugar regulation, and that background is useful context for understanding why researchers became interested in its possible effects in inflammatory conditions. Reducing body weight by 15–20% changes the inflammatory environment substantially, and in SURMOUNT-1 the average reduction at the highest dose was in that range, a degree of weight change that dermatologists treating HS consider clinically significant.

Is there actual evidence linking tirzepatide to HS improvement?

Honest answer: early-stage, and not yet from a controlled trial. The evidence base is currently made up of case reports, small observational series and mechanistic hypotheses rather than a randomised study with HS endpoints. Several case reports have described patients with moderate-to-severe HS who began tirzepatide for weight management and noticed fewer flares, reduced drainage and, in some cases, a longer interval between lesions over the months that followed. Dermatologists have started to flag these findings at conferences, and at least one prospective study is understood to be in planning.

There is also growing interest in whether GLP-1 receptor agonism has direct immunomodulatory effects independent of weight loss. GLP-1 receptors are expressed on immune cells including macrophages and T-cells, and preclinical data suggest activation of these receptors may dampen certain inflammatory signals. Tirzepatide additionally activates GIP receptors, making it the only dual-agonist weight-loss medicine licensed in the UK, and GIP receptor expression in skin tissue is another area being studied. None of this is yet translated into clinical guidance. The honest position is that the mechanism is biologically plausible, the early signals are interesting, but dermatology guidelines have not yet incorporated GLP-1 medicines. If you want to understand more about how tirzepatide works as a treatment, that overview covers the licensed evidence base in detail.

What does this mean if you have HS and are considering tirzepatide?

If you have HS and also meet the licensed eligibility criteria for tirzepatide (broadly, a BMI of 30 or above, or 27 or above with at least one weight-related health condition) then your HS may well be considered a relevant comorbidity as part of your clinical picture, even though it is not one of the named conditions in NICE's appraisal of tirzepatide (NICE TA1026). The decision sits with your prescriber. What that person will assess is your overall health, your other medications, and whether the potential benefits of tirzepatide outweigh any risks for you specifically.

It is also worth knowing that tirzepatide will not be suitable for everyone. There are contraindications and interactions a prescriber needs to check; for instance, if you are using oral contraceptives, an additional method of contraception is advised for the first four weeks of treatment and after each dose increase, because gastric slowing can affect pill absorption. These are the kinds of details a same-day clinical review at a regulated pharmacy should work through with you. Our frequently asked questions cover some of the more common eligibility queries if you want to read further before your consultation. One practical note: if treatment is approved, your first pen arrives via DPD the next working day in a plain, unbranded box, no indication of what is inside.

If you are looking for a broader view of the weight-loss medicines available in the UK, the treatment overview page sets those out clearly. Cost is a real consideration for many people, and the Mounjaro pricing context page explains what private treatment typically covers and why the price varies by dose and provider.

What should someone with HS actually do next?

Talk to a dermatologist about your HS management and to a prescriber about weight management, ideally both, and ideally in conversation with each other. HS has its own established treatment pathway, ranging from topical antiseptics through antibiotics, biologics and, in severe cases, surgery. Weight loss through tirzepatide is not a replacement for any of those, but it may complement them, and our page on Mounjaro sets out the full picture of how the medicine is used for weight management in the UK. There is no scenario in which a prescriber should offer tirzepatide solely on the grounds that it might help HS; the medicine is assessed against its licensed use, and clinical suitability determines the outcome. People also sometimes ask how long they are likely to stay on treatment, and our guide to tirzepatide duration walks through what current evidence and clinical practice suggest about typical treatment length. If you are thinking ahead to practical questions about access, the page covering tirzepatide supply explains the current availability picture and what to expect once you start treatment, while our separate page on choosing a tirzepatide supplier outlines what to look for in a regulated provider.

If you meet the criteria for weight management treatment and want a clinical review that considers your full health picture (including conditions like HS) our prescribers review every consultation personally on the same day it is submitted. You can read more about our clinical team and the oversight that sits behind every decision. For any questions about logistics or how the process works, our support team is available seven days a week. When you are ready, you can speak to our prescribers through a free consultation with no obligation.